AppLovin Corporation

Since the beginning of 2026, the previously popular ad platform with investors has lost about a third of its value

AppLovin stock collapsed after a strong report. What didn't it convince Wall Street of?

Cloudflare, Inc.

The company's securities have fallen in price by 4% since the beginning of 2026

Cloudflare will benefit from a 'dead internet', say analysts. Is it worth buying shares

McDonald's Corporation

The company's bet on more budget-friendly and favorable offerings has started to yield results

McDonald's posted its best U.S. sales growth in two years. What's the secret? 

Moderna, Inc.

The decrease in quotations in the moment was the strongest for nine months

Moderna's stock fell due to regulatory concerns. A more important development is also under attack

Mattel, Inc.

Hasbro, Inc.

Barbie's sales revenue declined for the second year in a row

Barbie maker's stock plunges, Wall Street downgrades. What went wrong?

LVMH Moet Hennessy - Louis Vuitton, Societe Europeenne

French billionaire Bernard Arnault began actively buying shares of the world's largest luxury holding LVMH after the <a href="https://oninvest.com/article/vladelec-louis-vuitton-otcitalsa-o-slabom-prazdnicnom-kvartale-nadezda-na-kitaj">publication of</a> its late January disappointing investors and falling prices, <a href="https://www.bloomberg.com/news/articles/2026-02-11/arnault-snaps-up-lvmh-shares-after-vowing-to-own-more-than-50">writes</a> Bloomberg. Arnault has already sent to buy securities more than € 400 million. In late January during the presentation of financial results of the holding businessman said that his family group wants to increase its stake in LVMH in 2026 to more than 50%.

Europe's richest man bought LVMH shares on a drawdown. Should we follow his example?

Meta Platforms, Inc.

Ekman appears to be high on Mark Zuckerberg's company's prospects in the AI race

Billionaire Ackman's hedge fund disclosed a big stake in Meta. How else has the portfolio changed?

Warner Bros. Discovery, Inc.

Paramount Skydance Corporation

Netflix, Inc.

Investment company Ancora Holdings has acquired a stake in Warner Bros. Discovery and said it intends to oppose the sale of studios and streaming assets to Netflix, Reuters<a href="https://www.reuters.com/legal/transactional/ancora-capital-builds-stake-warner-bros-plans-oppose-netflix-deal-2026-02-11/"> writes</a>. The activist investment company considers Paramount Skydance's offer more favorable and less risky from the point of view of regulators.

Warner Bros. has an activist investor. Does this threaten the Netflix deal?

The price of Brent crude oil on February 11 increased by almost 2% at an intraday high and crossed the $70.7 per barrel mark. The last time oil prices <a href="https://oninvest.com/article/neft-vpervye-s-sentabra-probila-70-za-barrel-analitiki-zdut-ese-bol-sego-rosta">were</a> at this level was at the end of January. WTI, meanwhile, jumped more than 2% to $65.8.

"Tensions support prices": oil jumped 2% to breach $70 a barrel

The Kraft Heinz Company

Dissatisfaction with plans to split up Kraft Heinz was previously expressed by Warren Buffett, Berkshire Hathaway - the food giant's largest shareholder

Kraft Heinz has put the separation of the business on pause. Buffett was unhappy with these plans

Employment growth in the United States accelerated in January and exceeded economists' expectations more than twice. A total of 130 thousand new jobs outside the agricultural sector <a href="https://www.bls.gov/news.release/empsit.nr0.htm">appeared</a> last month after 50 thousand a month earlier, according to data from the Bureau of Labor Statistics of the U.S. Department of Labor. While analysts expected to see this figure in January at 55 thousand (according to The Wall Street Journal) and 70 thousand, according to the estimates of economists surveyed by Reuters.

US employment data - better than forecasts. Why the analyst thinks: the market is "frozen"

Viking Therapeutics, Inc.

Novo Nordisk A/S

Eli Lilly and Company

Risk-tolerant investors should not ignore shares of biotech Viking Therapeutics, Motley Fool analyst Adria Cimino <a href="https://www.fool.com/investing/2026/02/11/viking-therapeutics-the-undertheradar-glp1-contend/">argues</a>. This is because the company is developing an obesity drug that could compete with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound in the near term.

Oil